Nadim Ahmed (Bristol Myers Squibb)

Bris­tol My­er­s' top hema­tol­ogy ex­ec is on his way out — right on the heels of a $6B CVR im­plo­sion

Four­teen days af­ter the $6.3 bil­lion CVR tied to the ap­proval of liso-cel went up in smoke, one of the top ex­ecs in charge of the work at Bris­tol My­ers Squibb is prepar­ing to step out of his job.

Mizuho an­a­lyst Sal­im Syed, who’s been fol­low­ing every twist and turn in the CVR saga, told in­vestors on Thurs­day morn­ing that Nadim Ahmed is on his way out. Syed’s note:

Re­call, Ahmed is EVP and Pres­i­dent of Hema­tol­ogy at BMY (i.e. JCAR017 and bb2121 are both hema­to­log­i­cal drugs). He’s still list­ed on the BMY man­age­ment page. This is true — he’s still tech­ni­cal­ly there. How­ev­er, I have con­firmed w/ BMY that his last day is to­mor­row, Fri­day 1/15. To my best knowl­edge, Ahmed does not have an­oth­er job lined up post his de­par­ture to­mor­row.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.